Drug metabolism and drug interactions · 2020 · 10 citations · 22 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsAge-related Pharmacokinetic DifferencesAge-related PharmacokineticsAnticoagulant Therapy In Older AdultsArrhythmia PharmacotherapyAtrial FibrillationCardiovascular Pharmacotherapy In Older AdultsAtrial Fibrillation Drug InteractionsBleedingCalcium Channel Blocker InteractionsCyp3a4 InteractionsSteady-state ConcentrationSteady-state Plasma ConcentrationSteady-state Trough ConcentrationVerapamil Therapy
Abstract Objectives For revealing the peculiarities of the drug–drug interaction of rivaroxaban (substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs) (verapamil – inhibitor CYP3A4 and P-gp and amlodipine – substrate CYP3A4) in patients 80 years and older with nonvalvular atrial fibrillation (NAF) we studied 128 patients. Methods All patients were divided into groups depending on the therapy taken: the 1st – rivaroxaban + amlodipine (n=51), the 2nd – rivaroxaban + verapamil (n=30), the control group – rivaroxaban without CCBs (n=47). A trough steady-state plasma concentration ( C min,ss ) of rivaroxaban, prothrombin time (PT) in the blood plasma and the event of clinically relevant non-major (CRNM) bleeding were assessed for each patient. Results Patient in group 2 had higher C min,ss of rivaroxaban, PT and CRNM than subjects in the control group (Me 73.8 [50.6–108.8] ng/mL vs. 40.5 [25.6–74.3] ng/mL; Me 14.8 [13.4–17.3] s vs. 13.8 [12.6–14.4] s; 34% vs. 13%, respectively, p<0.05 for all). When compared, the PT and complication rate in group 1 with the control group C min,ss of rivaroxaban were practically the same (p>0.05 for all). Conclusions In patients ≥80 years with NAF, the use of rivaroxaban in combination with verapamil may not be safe and can lead to CRNM bleeding.
22
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. · European Heart Journal · 2018 · 10.4K citations · Full text
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Worldwide Epidemiology of Atrial Fibrillation
Sumeet S. Chugh, Rasmus Havmoeller, Kumar Narayanan et al. · Circulation · 2013 · 4.5K citations · Full text